Work

Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)

Year: 2016

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw435.34

Authors: R.S. Herbst, J. Martin-Liberal, E. Calvo, N. Isambert, J.C. Bendell, P. Cassier, J.L. Perez-Gracia, J. Yang, J. Rege, G. Mi, D. Ferry, L. Paz-Ares

Institutions: Yale University, Vall d'Hebron Hospital Universitari, Centre Georges François Leclerc, Tennessee Oncology, Centre Léon Bérard, Universidad de Navarra, Eli Lilly (United States), Hospital Universitario Virgen del Rocío

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2588781634

FWCI: 1.26

Cites:

Cited by: 12

Related to: 10